Barclays Initiates Coverage of Sutro Biopharma (STRO) with Overweight Recommendation
Fintel reports that on May 28, 2026, Barclays initiated coverage of Sutro Biopharma (NasdaqGM:STRO) with a Overweight recommendation.
Analyst Price Forecast Suggests 14.40% Upside
As of May 14, 2026, the average one-year price target for Sutro Biopharma is $33.97/share. The forecasts range from a low of $9.09 to a high of $57.75. The average price target represents an increase of 14.40% from its latest reported closing price of $29.69 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sutro Biopharma is 172MM, an increase of 68.00%. The projected annual non-GAAP EPS is -2.37.
What is the Fund Sentiment?
There are 76 funds or institutions reporting positions in Sutro Biopharma. This is an increase of 17 owner(s) or 28.81% in the last quarter. Average portfolio weight of all funds dedicated to STRO is 0.35%, an increase of 320.74%. Total shares owned by institutions increased in the last three months by 171.14% to 14,394K shares. 
The put/call ratio of STRO is 0.50, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 1,252K shares representing 7.56% ownership of the company.
Affinity Asset Advisors holds 1,070K shares representing 6.46% ownership of the company. In its prior filing, the firm reported owning 748K shares , representing an increase of 30.03%. The firm increased its portfolio allocation in STRO by 178.87% over the last quarter.
Samsara BioCapital holds 1,063K shares representing 6.42% ownership of the company. In its prior filing, the firm reported owning 205K shares , representing an increase of 80.76%. The firm increased its portfolio allocation in STRO by 953.91% over the last quarter.
Kynam Capital Management holds 873K shares representing 5.27% ownership of the company. In its prior filing, the firm reported owning 480K shares , representing an increase of 45.04%. The firm increased its portfolio allocation in STRO by 278.26% over the last quarter.
Orbimed Advisors holds 801K shares representing 4.84% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.